Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 3/20 | 0.55 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844349 | 0.82 | SOAT1 (0.53) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9316324 | 0.80 | KMT2A (0.69) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2147650 | 0.79 | KMT2A (0.65) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9843880 | 0.79 | SOAT1 (0.53) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9843936 | 0.79 | SMN1; SMN2 (0.77) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6899771 | 0.78 | SOAT1 (0.62) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL14817544 | 0.78 | ALDH1A1 (0.63) | KMT2ALMNASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL2148218 | 0.78 | SMN1; SMN2 (0.70) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2605687 | 0.77 | ALDH1A1 (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL13328399 | 0.77 | NLRP3 (0.58) | SOAT1SOAT2KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | claimed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | SOAT1 17/4885SOAT2 28/4885KMT2A 2011/4885 |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | SOAT1 17/4885SOAT2 28/4885KMT2A 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.